Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Core Insights - Pluri, Inc. has expanded its manufacturing agreement with Remedy Cell Ltd., focusing on stem cell-derived, cell-free therapeutics for fibrotic conditions [1][4] Group 1: Collaboration and Achievements - The collaboration has successfully integrated Remedy Cell's proprietary manufacturing process into Pluri's GMP facility, completing training and qualification for the manufacturing team [2][3] - Several clinical-grade batches of Remedy Cell's lead candidate have been manufactured, intended for use in an initial Phase 1b clinical trial, marking significant progress in clinical development [2][3] Group 2: Future Plans and Commitment - PluriCDMO™ will continue to provide manufacturing and process-development support as Remedy Cell advances its clinical and pre-commercial programs, highlighting the productive partnership [4] - Both companies express a strong commitment to advancing next-generation, cell-free biologics to address unmet medical needs [4][5] Group 3: Company Backgrounds - Pluri is a biotechnology company specializing in scalable cell-based solutions and has a strong intellectual property portfolio, focusing on regenerative medicine and CDMO services [6] - Remedy Cell is a clinical-stage biopharmaceutical company developing innovative therapies for fibrotic diseases, with its lead product RC-0315 showing potential in treating Idiopathic Pulmonary Fibrosis (IPF) [8][9]